Login / Signup

Early experience of seven hepatocellular carcinoma cases treated with regorafenib.

Shinsuke UchikawaTomokazu KawaokaHiroshi AikataKenichiro KodamaYuki InagakiMasahiro HatookaKei MorioTakashi NakaharaEisuke MurakamiAkira HiramatsuMasataka TsugeMichio ImamuraYoshiiku KawakamiKazuaki Chayama
Published in: Clinical case reports (2018)
Regorafenib became second-line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier.
Keyphrases
  • metastatic colorectal cancer
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • replacement therapy